An exploratory analysis shows a reduction in extrathoracic metastases and prolonged time to progression or death due to any metastases with durvalumab vs placebo.

BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...

Panelists discuss how the five-year prognosis for advanced non-small cell lung cancer (NSCLC) has improved with PD-1 inhibitors, showing promising overall survival (OS) and progression-free survival ...

Feb. 6, 2025 — Scientists have created a new low-cost, fast response sensor to detect lung cancer biomarkers, paving the way for the development of screening devices to spot the disease even ...

PGV001, a personalized cancer vaccine, induced immune responses across various cancer types like breast and urothelial cancer ...

A new study validates NRG1 gene fusions as a targetable driver of advanced NRG1 fusion-positive cancers, adding support for ...

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.

This paper explores the potential of mitochondrial-associated programmed-cell-death (mtPCD) patterns as biomarkers for ...

Enriqueta Felip, MD, PhD, discusses the phase 3 3475A-D77 study of subcutaneous pembrolizumab plus chemotherapy in metastatic non–small cell lung cancer.

Subcutaneous pembrolizumab reduces time demands for both the patient and clinician, all while providing a consistent efficacy and safety profile with IV pembrolizumab.

The latest data from Johnson and Johnson's Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso ...